<DOC>
	<DOCNO>NCT01848834</DOCNO>
	<brief_summary>This study do investigate safety , tolerability anti-tumor activity pembrolizumab ( MK-3475 ) participant advanced triple negative breast cancer ( TNBC ) ( Cohort A ) , advanced head neck cancer ( Cohorts B B2 ) , advanced urothelial cancer ( Cohort C ) , advance gastric cancer ( Cohort D )</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Advanced Solid Tumors ( MK-3475-012/KEYNOTE-012 )</brief_title>
	<detailed_description>Amendment 2 protocol add new study arm ( Cohort B2 ) participant advanced head neck cancer receive low dose pembrolizumab ( MK-3475 ) every three week ( Q3W ) ; participant program cell death ligand 1 ( PD-L1 ) -negative tumor also analyze separately .</detailed_description>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically cytologicallyconfirmed diagnosis tumor recurrent , metastatic , persistent : For Cohort A triple negative breast cancer ( estrogen , progesterone , human epidermal growth factor receptor 2 [ HER2 ] negative ) For Cohort B squamous cell carcinoma head neck ( include HPVpositive head neck squamous cell cancer ) . For Cohort C urothelial tract cancer renal pelvis , ureter , bladder , urethra ( transitional cell nontransitional cell histology ) For Cohort D adenocarcinoma stomach gastroesophageal junction For Cohort B2 squamous cell carcinoma head neck ( HPVpositive negative head neck squamous cell cancer ) Any number prior treatment regimens Measurable disease Eastern Cooperative Oncology Group ( ECOG ) Performance status 0 1 Female participant childbearing potential must willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study treatment Male participant must agree use adequate method contraception start first dose study therapy 120 day last dose study treatment Currently participate in/has participate study investigational agent use investigational device within 4 week first dose study treatment Diagnosis immunosuppression receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study treatment Anticancer monoclonal antibody treatment within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier Chemotherapy , target small molecule therapy radiation therapy within 2 week prior study Day 1 recover adverse event due previously administer agent Known additional malignancy progress require active treatment except basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent Evidence interstitial lung disease Active infection require systemic therapy Known psychiatric substance abuse disorder Pregnant , breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment Prior therapy antiprogrammed cell death 1 ( PD1 ) , antiprogrammed cell death 1 ligand 1 ( PDL1 ) , antiPDL2 , antiCD137 antibody , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody Known history human immunodeficiency virus ( HIV ) Known active Hepatitis B Hepatitis C Received live vaccine within 30 day prior start study treatment Is immediate family member ( e.g. , spouse , parent/legal guardian , sibling child ) Investigational site Sponsor staff directly involve trial , unless prospective Independent Review Board ( IRB ) approval ( Chair Designee ) give allow exception criterion specific participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>